FrancophonIA/ELRC3.0 huggingface dataset:
English: A dose of 300 mg/kg/day to rats was associated with a ceftolozane plasma exposure (AUC) value lower than the ceftolozane plasma AUC value at the highest recommended human dose of 2 grams every 8 hours.
Croatian: U štakora je doza od 300 mg/kg/dan bila povezana s vrijednošću izloženosti ceftolozanu u plazmi (AUC) koja je niža od vrijednosti AUC-a ceftolozana u plazmi kod najviše preporučene doze u ljudi od 2 g svakih 8 sati.
English: However, if you have any concerns you should let your doctor, nurse or pharmacist know immediately.
Croatian: Međutim, ako ste zabrinuti zbog toga, odmah obavijestite svog liječnika, medicinsku sestru ili ljekarnika.
English: For IV use after reconstitution and dilution
Croatian: Za i.v. primjenu nakon rekonstitucije i razrjeđivanja
English: The effects of ceftolozane and tazobactam on fertility in humans have not been studied.
Croatian: Učinci ceftolozana i tazobaktama na plodnost u ljudi nisu ispitani.
English: Peri/postnatal development was impaired (reduced pup weights, increase in stillbirths, increase in pup mortality) concurrent with maternal toxicity after intraperitoneal administration of tazobactam in the rat.
Croatian: U štakora je perinatalni/postnatalni razvoj bio narušen (smanjena tjelesna težina mladunčadi, povećanje mrtvorođenosti, povećanje mortaliteta mladunčadi) usporedno s toksičnošću za majku nakon intraperitonealne primjene tazobaktama.
English: Inflammation of the large intestine due to C. difficile bacteria, inflammation of the stomach, abdominal distension, indigestion, excessive gas in stomach or bowel, obstruction of the intestine, yeast infection in the mouth (thrush), yeast infection of female genitalia, fungal urinary tract infection, increase in sugar (glucose) levels (from blood tests), decrease in magnesium levels (from blood tests), decrease in phosphate levels (from blood tests), ischemic stroke (stroke caused by reduced blood flow in brain), irritation or inflammation of a vein at injection site, venous thrombosis (blood clot in a vein), low red blood cell counts, atrial fibrillation (rapid or irregular heartbeat), fast heart beat, angina pectoris (chest pain or feeling of tightness, pressure or heaviness in chest), itchy rash or swellings on the skin, hives, Coombs test positive (a blood test that looks for antibodies that may fight against your red blood cells), kidney problems, kidney disease, shortness of breath
Croatian: Manje česte nuspojave (mogu se javiti u do 1 na 100 osoba): upala debelog crijeva uzrokovana bakterijom C. difficile, upala želuca, nadimanje trbuha, probavne tegobe, prekomjerno nakupljanje plina u želucu ili crijevima, opstrukcija crijeva, gljivična infekcija kandidom u usnoj šupljini, gljivična infekcija ženskih spolnih organa, gljivična infekcija mokraćnog sustava, povišena razina šećera (glukoze) (na krvnim pretragama), smanjena razina magnezija (na krvnim pretragama), smanjena razina fosfata (na krvnim pretragama), ishemijski moždani udar (moždani udar uzrokovan smanjenim protokom krvi u mozgu), nadraženost ili upala vene na mjestu primjene lijeka, venska tromboza (krvni ugrušak u veni), nizak broj crvenih krvnih stanica, fibrilacija atrija (ubrzani ili nepravilni otkucaji srca), brzi otkucaji srca, angina pektoris (bol u prsnom košu ili osjećaj stezanja, pritiska ili težine u prsnom košu), osip ili otekline na koži koje svrbe, koprivnjača, pozitivan Coombsov test (krvna pretraga kojom se traže protutijela koja napadaju crvene krvne stanice), tegobe s bubrezima, bolest bubrega, nedostatak zraka.
English: Ceftolozane is eliminated in the urine as unchanged parent substance and thus does not appear to be metabolised to any appreciable extent.
Croatian: Ceftolozan se eliminira urinom u neizmijenjenom izvornom obliku pa se stoga čini da se ne metabolizira u nekom znatnijem opsegu.
English: Effect on renal function
Croatian: Učinak na funkciju bubrega
English: Complicated intra-abdominal infection*
Croatian: Komplicirana intraabdominalna infekcija*
English: After reconstitution with 10 mL diluent, the total volume of the solution in the vial is 11.4 mL, which contains 88 mg/mL of ceftolozane and 44 mg/mL of tazobactam.
Croatian: Nakon rekonstitucije s 10 ml otapala, ukupni volumen otopine u bočici je 11,4 ml, a sadrži 88 mg/ml ceftolozana i 44 mg/ml tazobaktama.
English: One of the active ingredients, ceftolozane, may have harmful effects if it reaches the aquatic environment (see section 5.3).
Croatian: Jedna od djelatnih tvari, ceftolozan, može imati štetne učinke ako dospije u vodeni okoliš (vidjeti dio 5.3).
English: Powder for concentrate for solution for infusion 10 vials
Croatian: Prašak za koncentrat za otopinu za infuziju 10 bočica
English: See section 4.2 for recommended dose regimens for Zerbaxa based on indication and renal function.
Croatian: Vidjeti dio 4.2 za preporučene režime doziranja lijeka Zerbaxa na temelju indikacije i funkcije bubrega.
English: Do not throw away any unused medicinal product or waste material via wastewater.
Croatian: Nikada nemojte nikakve neiskorištene lijekove ili otpadni materijal bacati u otpadne vode.
English: What Zerbaxa contains - The active substances are ceftolozane and tazobactam.
Croatian: Što Zerbaxa sadrži - Djelatne tvari su ceftolozan i tazobaktam.
English: For tazobactam the PD index associated with efficacy was determined to be the percentage of the dose interval during which the plasma concentration of tazobactam exceeds a threshold value (%T > threshold).
Croatian: Za tazobaktam je utvrđeno da je farmakodinamički indeks koji se povezuje s djelotvornošću postotak doznog intervala tijekom kojega koncentracija tazobaktama u plazmi premašuje graničnu vrijednost (%T>granične vrijednosti).
English: Adverse reactions not observed in clinical studies, but seen in animals at exposure levels similar to clinical exposure levels and with possible relevance to clinical use were as follows: ceftolozane administered to rats during pregnancy and lactation was associated with a decrease in auditory startle response in postnatal day (PND) 60 male pups at maternal doses of 300 and 1,000 mg/kg/day.
Croatian: Nuspojave koje nisu zabilježene u kliničkim ispitivanjima, ali su zapažene u životinja pri razinama izloženosti sličnim razinama izloženosti u ljudi i s mogućom važnošću za kliničku primjenu, bile su sljedeće: ceftolozan primijenjen u štakorica tijekom graviditeta i laktacije bio je povezan sa smanjenom reakcijom straha na zvučne podražaje 60. postnatalnog dana u muške mladunčadi kad su njihove majke primale doze od 300 i 1000 mg/kg/dan.
English: The highest single dose of Zerbaxa used in clinical trials was 3 g / 1.5 g of ceftolozane/tazobactam administered to healthy volunteers.
Croatian: Najviša jednokratna doza lijeka Zerbaxa primijenjena u kliničkim ispitivanjima bila je 3 g/1,5 g ceftolozana/tazobaktama i to kod zdravih dobrovoljaca.
English: The recommended intravenous dose regimen for patients with creatinine clearance > 50 mL/min is shown by infection type in Table 1.
Croatian: Preporučeni režim intravenskog doziranja u bolesnika s klirensom kreatinina >50 ml/min prikazan je prema vrsti infekcije u tablici 1.
English: Free plasma ceftolozane concentrations were greater than 8 mcg/mL over 70% of an 8-hour period; free tazobactam concentrations were greater than 1 mcg/mL over 60% of an 8-hour period.
Croatian: Koncentracija slobodnog ceftolozana u plazmi bila je veća od 8 μg/ml tijekom 70% 8-satnog razdoblja; koncentracija slobodnog tazobaktama bila je veća od 1 μg/ml tijekom 60% 8-satnog razdoblja.
English: The European Medicines Agency has deferred the obligation to submit the results of studies with Zerbaxa in one or more subsets of the paediatric population in complicated intra-abdominal infection, complicated urinary tract infection, and hospital-acquired pneumonia, including ventilator-associated pneumonia (see section 4.2 for information on paediatric use).
Croatian: Europska agencija za lijekove odgodila je obvezu podnošenja rezultata ispitivanja lijeka Zerbaxa u jednoj ili više podskupina pedijatrijske populacije u kompliciranim intraabdominalnim infekcijama, kompliciranim infekcijama mokraćnog sustava i bolničkoj pneumoniji, uključujući pneumoniju povezanu s mehaničkom ventilacijom (vidjeti dio 4.2 za informacije o pedijatrijskoj primjeni).
English: Susceptible Resistant
Croatian: Osjetljiv Rezistentan
English: With haemodialysis, the dose should be administered immediately following completion of dialysis (see section 4.2).
Croatian: Kod hemodijalize, dozu treba primijeniti odmah nakon završetka dijalize (vidjeti dio 4.2).
English: Patients who have a history of hypersensitivity to cephalosporins, penicillins or other beta-lactam antibacterial agents may also be hypersensitive to ceftolozane/tazobactam.
Croatian: Bolesnici koji u anamnezi imaju preosjetljivost na cefalosporine, peniciline ili druge beta-laktamske antibiotike mogu biti preosjetljivi i na ceftolozan/tazobaktam.
English: Ceftolozane/tazobactam is not active against bacteria that produce beta-lactamase enzymes which are not inhibited by tazobactam.
Croatian: Ceftolozan/tazobaktam nije djelotvoran protiv bakterija koje proizvode enzime beta-laktamaze koje tazobaktam ne inhibira.
English: Zerbaxa contains sodium
Croatian: Zerbaxa sadrži natrij
English: Table 3: Adverse reactions identified during clinical trials with ceftolozane/tazobactam System organ class
Croatian: Tablica 3: Nuspojave ustanovljene tijekom kliničkih ispitivanja s ceftolozanom/tazobaktamom
English: Clinical efficacy data in patients with complicated lower urinary tract infection are limited.
Croatian: Podaci o kliničkoj djelotvornosti u bolesnika s kompliciranom infekcijom donjeg dijela mokraćnog sustava su ograničeni.
English: Ceftolozane and tazobactam were not substrates for P-gp or BCRP, and tazobactam was not a substrate for OCT2, in vitro at therapeutic plasma concentrations.
Croatian: Ceftolozan i tazobaktam nisu bili supstrati za P-gp ili BCRP, a tazobaktam nije bio supstrat za OCT2, in vitro pri terapijskim koncentracijama u plazmi.
English: Excipient with known effect Each vial contains 10 mmol (230 mg) of sodium.
Croatian: Pomoćna tvar s poznatim učinkom Jedna bočica sadrži 10 mmol (230 mg) natrija.
English: The ceftolozane/tazobactam dose should be adjusted based on renal function (see section 4.2, Table 2).
Croatian: Dozu ceftolozana/tazobaktama treba prilagoditi na temelju funkcije bubrega (vidjeti dio 4.2, tablica 2).
English: After a single dose of ceftolozane/tazobactam, renal clearance of ceftolozane (3.41 - 6.69 L/h) was similar to plasma clearance (4.10 - 6.73 L/h) and similar to the glomerular filtration rate for the unbound fraction, suggesting that ceftolozane is eliminated by the kidney via glomerular filtration.
Croatian: Nakon jednokratne doze ceftolozana/tazobaktama, bubrežni klirens ceftolozana (3,41-6,69 l/h) bio je sličan klirensu iz plazme (4,10-6,73 l/h) i sličan brzini glomerularne filtracije nevezane frakcije, što ukazuje na to da se ceftolozan eliminira putem bubrega glomerularnom filtracijom.
English: Zerbaxa is used in adults to treat complicated infections within the abdomen, kidney and urinary system infections, and an infection of the lungs called “pneumonia”.
Croatian: Zerbaxa se primjenjuje u odraslih za liječenje kompliciranih infekcija u trbuhu, infekcija bubrega i mokraćnog sustava te infekcije pluća koja se naziva "pneumonija".
English: Fertility studies in rats showed no effect on fertility and mating after intraperitoneal administration of tazobactam or intravenous administration of ceftolozane (see section 5.3).
Croatian: Ispitivanja plodnosti na štakorima pokazala su da nema učinka na plodnost i parenje nakon intraperitonealne primjene tazobaktama ili intravenske primjene ceftolozana (vidjeti dio 5.3).
English: This is equivalent to 11.5% of the recommended maximum daily dietary intake of sodium for an adult.
Croatian: To odgovara 11,5% preporučenog maksimalnog dnevnog unosa soli za odraslu osobu.
English: Ceftolozane administered to rats during pregnancy and lactation was associated with a decrease in auditory startle response in postnatal day (PND) 60 male pups (see section 5.3).
Croatian: Primjena ceftolozana u štakora tijekom graviditeta i laktacije bila je povezana sa smanjenom reakcijom straha na zvučne podražaje 60. postnatalnog dana u muške mladunčadi (vidjeti dio 5.3).
English: 1, flatulence 1, ileus paralytic
Croatian: 1, paralitički ileus
English: 3, increased serum gamma-glutamyl transpeptidase (GGT)
Croatian: 3, povišene vrijednosti gama-glutamil transpeptidaze (GGT) u serumu
English: Adverse reactions are classified according to MedDRA system organ class and frequency.
Croatian: Nuspojave su kategorizirane prema MedDRA klasifikaciji organskih sustava i učestalosti.
English: This is equivalent to 13.3% of the recommended maximum daily dietary intake of sodium for an adult.
Croatian: To odgovara 13,3% preporučenog maksimalnog dnevnog unosa soli za odraslu osobu.
English: Carcinogenicity studies with ceftolozane/tazobactam have not been conducted.
Croatian: Nisu provedena ispitivanja kancerogenosti ceftolozana/tazobaktama.
English: Paediatric patients
Croatian: Pedijatrijski bolesnici
English: In clinical trials of complicated intra-abdominal infections and complicated urinary tract infections, including pyelonephritis, the efficacy of ceftolozane/tazobactam was lower in patients with moderate renal impairment compared with those with normal or mildly impaired renal function at baseline.
Croatian: U kliničkim ispitivanjima kompliciranih intraabdominalnih infekcija i kompliciranih infekcija mokraćnog sustava, uključujući i pijelonefritis, djelotvornost ceftolozana/tazobaktama bila je manja u bolesnika s umjereno oštećenom funkcijom bubrega nego u onih s normalnom ili blago oštećenom funkcijom bubrega na početku ispitivanja.
English: - Complicated intra-abdominal infections (see section 4.4); - Acute pyelonephritis; - Complicated urinary tract infections (see section 4.4); - Hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP).
Croatian: - komplicirane intraabdominalne infekcije (vidjeti dio 4.4); - akutni pijelonefritis; - komplicirane infekcije mokraćnog sustava (vidjeti dio 4.4); - bolnička pneumonija (engl. hospital-acquired pneumonia, HAP), uključujući pneumoniju povezanu s mehaničkom ventilacijom (engl. ventilator-associated pneumonia, VAP).
English: - Hypersensitivity to the active substances or to any of the excipients listed in section 6.1; - Hypersensitivity to any cephalosporin antibacterial agent; - Severe hypersensitivity (e.g., anaphylactic reaction, severe skin reaction) to any other type of beta-lactam antibacterial agent (e.g., penicillins or carbapenems).
Croatian: - Preosjetljivost na djelatne tvari ili neku od pomoćnih tvari navedenih u dijelu 6.1; - Preosjetljivost na bilo koji cefalosporinski antibiotik; - Teška preosjetljivost (npr. anafilaktička reakcija, jaka kožna reakcija) na bilo koju drugu vrstu beta-laktamskog antibiotika (npr. peniciline ili karbapeneme).
English: Metallo-beta-lactamases (e.g., New Delhi metallo-beta-lactamase [NDM]) iv. Ambler Class D beta-lactamases (OXA-carbapenemases)
Croatian: serinske karbapenemaze (npr. karbapenemaze bakterije Klebsiella pneumoniae [KPC]) iii. metalo-beta-laktamaze (npr. New Delhi metalo-beta-laktamazu [NDM]) iv. beta-laktamaze Ambler klase D (OXA-karbapenemaze).
English: 20 mL vial (Type I clear glass) with stopper (bromobutyl rubber) and flip-off seal.
Croatian: Bočica od 20 ml (prozirno staklo tipa I) s čepom (bromobutilna guma) i zaštitnim zatvaračem.
English: The respective tazobactam dose normalized geometric mean AUC increased approximately up to 1.3-fold, 2-fold, and 4-fold.
Croatian: U tih se skupina geometrijska srednja vrijednost AUC-a tazobaktama normalizirana na dozu povećala do približno 1,3 puta, 2 puta odnosno 4 puta.
English: Uncommon (≥ 1/1,000 to < 1/100)
Croatian: Manje često (≥1/1000 i <1/100)
English: Clinical efficacy has not been established against the following pathogens although in vitro studies suggest that they would be susceptible to Zerbaxa in the absence of acquired mechanisms of resistance:
Croatian: Klinička djelotvornost protiv sljedećih patogena nije ustanovljena, iako ispitivanja in vitro ukazuju na to da bi mogli biti osjetljivi na lijek Zerbaxa u odsutnosti stečenih mehanizama rezistencije: Citrobacter freundii
English: Table 2: Recommended intravenous dose regimens for Zerbaxa in patients with creatinine clearance ≤ 50 mL/min
Croatian: Tablica 2: Preporučeni režimi intravenskog doziranja lijeka Zerbaxa u bolesnika s klirensom kreatinina ≤50 ml/min
English: No dose adjustment of ceftolozane/tazobactam based on age alone is recommended.
Croatian: Ne preporučuje se prilagodba doze ceftolozana/tazobaktama samo na temelju dobi.
English: For doses above 1 g ceftolozane and 0.5 g tazobactam, two vials are used.
Croatian: Za doze više od 1 g ceftolozana i 0,5 g tazobaktama moraju se upotrijebiti dvije bočice.
English: Acute pyelonephritis
Croatian: Akutni pijelonefritis
English: As this product is given by a doctor or other healthcare professional, it is very unlikely that you will be given too much Zerbaxa.
Croatian: Ako primite više lijeka Zerbaxa nego što ste trebali Budući da ovaj lijek daje liječnik ili neki drugi zdravstveni radnik, nije vjerojatno da ćete dobiti previše lijeka Zerbaxa.
English: The recommended dose of Zerbaxa is 1 g of ceftolozane and 0.5 g of tazobactam or 2 g of ceftolozane and 1 g of tazobactam every 8 hours, which is given into one of your veins (directly into the bloodstream).
Croatian: Preporučena doza lijeka Zerbaxa je 1 g ceftolozana i 0,5 g tazobaktama ili 2 g ceftolozana i 1 g tazobaktama svakih 8 sati, koja se daje u jednu od vena (izravno u krvotok).
English: See section 4.2 of the Summary of Product Characteristics for recommended dose regimens for Zerbaxa based on indication and renal function.
Croatian: Vidjeti dio 4.2 sažetka opisa svojstava lijeka za preporučene režime doziranja lijeka Zerbaxa na temelju indikacije i funkcije bubrega.
English: Do not use this medicine after the expiry date which is stated on the carton and vial after “EXP.” The expiry date refers to the last day of that month.
Croatian: Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kutiji i bočici iza oznake "EXP".
English: The most common adverse reactions (≥ 5% in a Phase 3 trial of hospital-acquired pneumonia, including ventilator-associated pneumonia) occurring in patients receiving Zerbaxa were diarrhoea, alanine aminotransferase increased, and aspartate aminotransferase increased and were generally mild or moderate in severity.
Croatian: Najčešće nuspojave (≥5% u kliničkom ispitivanju faze 3 kod bolničke pneumonije, uključujući i pneumoniju povezanu s mehaničkom ventilacijom) u bolesnika koji su primali lijek Zerbaxa bile su dijareja, povišena vrijednost alanin aminotransferaze i povišena vrijednost aspartat aminotransferaze te su općenito bile blage ili umjereno teške.
English: For intravenous use after reconstitution and dilution.
Croatian: Za primjenu u venu nakon rekonstitucije i razrjeđivanja.
English: - The other excipients are sodium chloride, arginine, and citric acid, anhydrous.
Croatian: - Druge pomoćne tvari su natrijev klorid, arginin i bezvodna citratna kiselina.
English: In vitro studies demonstrated that ceftolozane, tazobactam and the M1 metabolite of tazobactam did not inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 and did not induce CYP1A2, CYP2B6, or CYP3A4 at therapeutic plasma concentrations.
Croatian: Ispitivanja in vitro pokazala su da ceftolozan, tazobaktam i metabolit tazobaktama M1 nisu inhibirali CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 ili CYP3A4 i nisu inducirali CYP1A2, CYP2B6 ili CYP3A4 pri terapijskim koncentracijama u plazmi.
English: No dose adjustment of ceftolozane/tazobactam is recommended for hospital-acquired pneumonia, including ventilatorassociated pneumonia patients with augmented renal clearance.
Croatian: Ne preporučuje se prilagodba doze ceftolozana/tazobaktama u bolesnika s bolničkom pneumonijom, uključujući pneumoniju povezanu s mehaničkom ventilacijom, i pojačanim bubrežnim klirensom.
English: 1, increased serum alkaline phosphatase Clostridioides test positive
Croatian: 1, povišene vrijednosti alkalne fosfataze u serumu pozitivni rezultati testova na bakterije iz roda Clostridioides
English: Driving and using machines Zerbaxa may cause dizziness, which can affect your ability to drive and use machines.
Croatian: Zerbaxa može uzrokovati omaglicu, što može utjecati na Vašu sposobnost upravljanja vozilima ili rada sa strojevima.
English: Ceftolozane/tazobactam should be used with caution in patients with a history of any other type of hypersensitivity reaction to penicillins or other beta-lactam antibacterial agents.
Croatian: Ceftolozan/tazobaktam treba primjenjivati s oprezom u bolesnika koji u anamnezi imaju bilo koju drugu vrstu reakcije preosjetljivosti na peniciline ili druge beta-laktamske antibiotike.
English: The most common adverse reactions (≥ 3% in pooled Phase 3 trials of complicated intra-abdominal infections and complicated urinary tract infections, including pyelonephritis) occurring in patients receiving Zerbaxa were nausea, headache, constipation, diarrhoea, and pyrexia and were generally mild or moderate in severity.
Croatian: Najčešće nuspojave (≥3% u objedinjenim ispitivanjima faze 3 kod kompliciranih intraabdominalnih infekcija i kompliciranih infekcija mokraćnog sustava, uključujući i pijelonefritis) u bolesnika koji su primali lijek Zerbaxa bile su mučnina, glavobolja, konstipacija, dijareja i vrućica te su općenito bile blage ili umjereno teške.
English: Following administration of a single 1 g / 0.5 g IV dose of ceftolozane/tazobactam to healthy male adults greater than 95% of ceftolozane was excreted in the urine as unchanged parent substance.
Croatian: Nakon intravenske primjene jednokratne doze ceftolozana/tazobaktama od 1 g/0,5 g u zdravih odraslih muškaraca, više od 95% ceftolozana izlučilo se urinom u neizmijenjenom izvornom obliku.
English: The incidence of seroconversion to a positive direct Coombs test was 31.2% in patients receiving Zerbaxa and 3.6% in patients receiving meropenem in the hospital-acquired pneumonia, including ventilator-associated pneumonia clinical trial.
Croatian: Incidencija serokonverzije koju pokazuje pozitivni rezultat direktnog Coombsovog testa bila je 31,2% u bolesnika koji su u kliničkom ispitivanju kod bolničke pneumonije, uključujući pneumoniju povezanu s mehaničkom ventilacijom, primali lijek Zerbaxa i 3,6% u bolesnika koji su primali meropenem.
English: Alanine aminotransferase increased aspartate aminotransferase increased transaminases increased
Croatian: Pretrage povišene vrijednosti alanin aminotransferaze
English: Skin and subcutaneous tissue disorders
Croatian: Poremećaji kože i potkožnog tkiva osip urtikarija
English: For ceftolozane the time that the plasma concentration exceeds the minimum inhibitory concentration of ceftolozane for the infecting organism has been shown to be the best predictor of efficacy in animal models of infection.
Croatian: Za ceftolozan se najboljim pretkazateljem djelotvornosti u životinjskim modelima infekcije pokazalo vrijeme tijekom kojega koncentracija ceftolozana u plazmi premašuje minimalnu inhibitornu koncentraciju za organizam koji uzrokuje infekciju.
English: Gram-negative bacteria Escherichia coli Klebsiella pneumoniae Proteus mirabilis
Croatian: Gram-negativne bakterije Escherichia coli Klebsiella pneumoniae Proteus mirabilis
English: Plasma levels of ceftolozane/tazobactam do not increase appreciably following multiple IV infusions of up to 2.0 g / 1.0 g administered every 8 hours for up to 10 days in healthy adults with normal renal function.
Croatian: Razine ceftolozana/tazobaktama u plazmi nisu se zamjetno povećale nakon višestrukih intravenskih infuzija u dozama do 2,0 g/1,0 g primjenjivanih svakih 8 sati u razdoblju do najviše 10 dana u zdravih odraslih osoba s normalnom funkcijom bubrega.